@@ Revolutionary，changes have been made in the treatment of chronic hepatitis B(CHB)in the past decade.InChina,there are six approved agents，including two forms ofinterferon(conventional and pegylated)andfour oral nucleoside／nucleotide analogues(1amivudine，adefovir,entecavir and telbivudine)．The phase III registrationtrial of tenofovir disoproxil fumarate is ongoing and will be anticipated to come into the market in China within 2years．The availability of these multiple treatment options has led to expansion of treatment indications．However,the indefinite treatment duration with some therapies，the high costs ofHBV medications，the side effects associatedwith some treatments and the risks ofdrug resistance during long-term oral antiviral drugs treatment necessitatecareful balancing the risk and benefit prior to initiating treatment．